EA202192401A1 - Оптимизированный бесклеточный синтез плазмидного антигена инвазии в и родственные композиции и способы применения - Google Patents
Оптимизированный бесклеточный синтез плазмидного антигена инвазии в и родственные композиции и способы примененияInfo
- Publication number
- EA202192401A1 EA202192401A1 EA202192401A EA202192401A EA202192401A1 EA 202192401 A1 EA202192401 A1 EA 202192401A1 EA 202192401 A EA202192401 A EA 202192401A EA 202192401 A EA202192401 A EA 202192401A EA 202192401 A1 EA202192401 A1 EA 202192401A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ipab
- antigen
- free synthesis
- methods
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
В настоящем изобретении предусмотрен бесклеточный способ синтеза антигена, представляющего собой плазмидный антиген инвазии B (IpaB), ассоциированного с бактерией рода Shigella, включающий экзогенное добавление очищенного белка-шаперона IpgC к смеси, полученной посредством бесклеточного синтеза. В настоящем изобретении дополнительно предусмотрены мутантные варианты антигена IpaB, содержащие неприродные аминокислоты, включенные во время бесклеточного синтеза, обеспечивающие ковалентное конъюгирование с полисахаридом O-антигена Shigella. Дополнительно предусмотрены антигены IpaB и их конъюгаты, а также иммуногенные композиции, полученные с использованием синтезированных антигенов IpaB и их конъюгатов, и способы применения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828364P | 2019-04-02 | 2019-04-02 | |
PCT/US2020/025384 WO2020205584A1 (en) | 2019-04-02 | 2020-03-27 | Optimized cell-free synthesis of invasion plasmid antigen b and related compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192401A1 true EA202192401A1 (ru) | 2022-03-30 |
Family
ID=70416548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192401A EA202192401A1 (ru) | 2019-04-02 | 2020-03-27 | Оптимизированный бесклеточный синтез плазмидного антигена инвазии в и родственные композиции и способы применения |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220125907A1 (ru) |
EP (1) | EP3946443A1 (ru) |
JP (1) | JP2022527206A (ru) |
KR (1) | KR20210146392A (ru) |
CN (1) | CN114025789A (ru) |
AU (1) | AU2020253332A1 (ru) |
BR (1) | BR112021019826A2 (ru) |
CA (1) | CA3135489A1 (ru) |
EA (1) | EA202192401A1 (ru) |
IL (1) | IL286819A (ru) |
MA (1) | MA55528A (ru) |
MX (1) | MX2021012120A (ru) |
SG (1) | SG11202110803YA (ru) |
TW (1) | TW202102527A (ru) |
WO (1) | WO2020205584A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4200268A1 (en) * | 2020-08-19 | 2023-06-28 | Vaxcyte, Inc. | Carrier-protein polysaccharide conjugation methods |
CA3208716A1 (en) * | 2021-02-17 | 2022-08-25 | Peter T. Davey | Purification processes for polysaccharides and polypeptide conjugates thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU682877B2 (en) | 1993-05-28 | 1997-10-23 | Chiron Corporation | Peptide inhibitors of urokinase receptor activity |
US5972899A (en) * | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
CN1912106A (zh) * | 2005-08-09 | 2007-02-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种痢疾多价基因工程菌苗及其制备方法 |
AU2007349883B2 (en) * | 2007-03-27 | 2013-06-27 | The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research | Artificial invaplex |
TWI365882B (en) * | 2007-06-15 | 2012-06-11 | Univ Nat Chunghsing | Shigella ipab803 protein, producing method and coding nucleic acid thereof |
DK2349520T3 (en) | 2008-10-27 | 2016-08-15 | Glaxosmithkline Biologicals Sa | Purification Procedure for Group A Streptococcus Carbohydrate |
WO2011130544A2 (en) | 2010-04-14 | 2011-10-20 | Sutro Biopharma, Inc. | Monitoring a dynamic system by liquid chromatography-mass spectrometry |
WO2013020090A2 (en) | 2011-08-04 | 2013-02-07 | The Regents Of The University Of California | STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM |
DK2906592T3 (en) | 2012-10-12 | 2018-12-10 | Sutro Biopharma Inc | Proteolytic inactivation of selected proteins in bacterial extracts for enhanced expression |
PL3055321T3 (pl) | 2013-10-11 | 2019-02-28 | Sutro Biopharma, Inc. | SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINY |
CA2957118A1 (en) * | 2014-08-05 | 2016-02-11 | Francesco Berti | Carrier molecule for antigens |
JP7186166B2 (ja) * | 2016-12-30 | 2022-12-08 | バックスサイト・インコーポレイテッド | 非天然アミノ酸とのポリペプチド抗原接合体 |
WO2020010000A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
WO2020010016A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
-
2020
- 2020-03-27 EA EA202192401A patent/EA202192401A1/ru unknown
- 2020-03-27 JP JP2021559041A patent/JP2022527206A/ja active Pending
- 2020-03-27 CN CN202080040388.1A patent/CN114025789A/zh active Pending
- 2020-03-27 MA MA055528A patent/MA55528A/fr unknown
- 2020-03-27 EP EP20721034.5A patent/EP3946443A1/en active Pending
- 2020-03-27 TW TW109110651A patent/TW202102527A/zh unknown
- 2020-03-27 WO PCT/US2020/025384 patent/WO2020205584A1/en unknown
- 2020-03-27 AU AU2020253332A patent/AU2020253332A1/en active Pending
- 2020-03-27 MX MX2021012120A patent/MX2021012120A/es unknown
- 2020-03-27 CA CA3135489A patent/CA3135489A1/en active Pending
- 2020-03-27 SG SG11202110803YA patent/SG11202110803YA/en unknown
- 2020-03-27 BR BR112021019826A patent/BR112021019826A2/pt unknown
- 2020-03-27 KR KR1020217035696A patent/KR20210146392A/ko unknown
-
2021
- 2021-09-29 IL IL286819A patent/IL286819A/en unknown
- 2021-10-01 US US17/492,190 patent/US20220125907A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3946443A1 (en) | 2022-02-09 |
KR20210146392A (ko) | 2021-12-03 |
CN114025789A (zh) | 2022-02-08 |
SG11202110803YA (en) | 2021-10-28 |
US20220125907A1 (en) | 2022-04-28 |
CA3135489A1 (en) | 2020-10-08 |
MA55528A (fr) | 2022-02-09 |
JP2022527206A (ja) | 2022-05-31 |
IL286819A (en) | 2021-10-31 |
MX2021012120A (es) | 2021-11-03 |
AU2020253332A1 (en) | 2021-11-25 |
BR112021019826A2 (pt) | 2021-12-07 |
TW202102527A (zh) | 2021-01-16 |
WO2020205584A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7248247B2 (ja) | Wt1抗原ペプチドコンジュゲートワクチン | |
ES2335557T3 (es) | Conjugados de peptido-polisacarido. | |
EA202192401A1 (ru) | Оптимизированный бесклеточный синтез плазмидного антигена инвазии в и родственные композиции и способы применения | |
AU2012244675B2 (en) | Novel binder-drug conjugates (ADCs) and their use | |
JP2018510864A (ja) | トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体 | |
JP2018513120A (ja) | 新規アマトキシン−抗体コンジュゲート | |
RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
CY1105737T1 (el) | Εμβολιο αναλογου βητα -amyloid και επιτοπου -τ- κυτταρου | |
US5606030A (en) | Coconjugates of OMPC, HIV related peptides and anionic moieties | |
TW202015739A (zh) | 剪接調節抗體-藥物結合物及其使用方法 | |
JP2022500413A (ja) | Toll様受容体アゴニストの抗体コンジュゲート | |
AP1891A (en) | HIV immunogenic compositions and methods. | |
EP3030545A2 (en) | Amino acid derivatives | |
JP2019089802A (ja) | Erap1によるトリミング機能をきっかけとしたコンジュゲートワクチン | |
MX2021014226A (es) | Arn terapeutico para cancer de ovario. | |
DK1629002T3 (da) | Fremgangsmåde til syntetisering af konformationalt hæmmede peptider, peptidometika og anvendelse deraf som syntetiske vacciner | |
EP4301417A1 (en) | Tlr7 and tlr8 agonists for the treatment of cancer and/or infectious diseases | |
EA200400897A1 (ru) | Иммуногенные композиции из вариабельных пептидных эпитопов и способ их получения | |
MX2009000717A (es) | Composicion para vacuna y metodo para inmunizacion. | |
EA200500480A1 (ru) | Иммунизация против аутологичного грелина | |
WO2022175222A1 (en) | Cryptophycin compounds and conjugates thereof | |
RU2012109467A (ru) | Синтетические иммуногенные конструкции для выработки антител, связывающих вирус гепатита с | |
WO2020039387A1 (en) | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | |
Luo | The Chemical Biology Approaches for Novel Therapeutics | |
EA201991559A1 (ru) | Конъюгаты полипептид-антиген с неприродными аминокислотами |